Abstract INTRODUCTION: Based on reports, infection with Mycobacterium tuberculosis is believed to induce the development of antibodies that are considered to be biological indicators for the diagnosis of some other diseases. However, conflicting results have been published regarding the presence of antineutrophil cytoplasmic antibodies (ANCAs) in patients with tuberculosis. We aim to study the seroprevalence of ANCA in a population of Chinese patients with tuberculosis, which may lead to the misdiagnosis of vasculitic disorders. METHODS: The study was conducted from January 2016 to May 2017 to evaluate the presence of ANCA in 103 Chinese patients using indirect immunofluorescent assay. An enzyme-linked immunosorbent assay was performed for anti-myeloperoxidase (MPO) and anti-proteinase 3 (PR3) detection. RESULTS: Perinuclear ANCA (p-ANCA) was detected in 4.8% (5/103) of patients, whereas cytoplasmic ANCA (c-ANCA) was not detected; 1.9% (2/103) of patients with tuberculosis was positive for anti-MPO antibodies, and none had anti-PR3 antibodies. Both anti-MPO-positive patients were diagnosed with ANCA-associated vasculitides. CONCLUSIONS: ANCA positivity may be more related to vasculitis and immunological disorders than to a M. tuberculosis infection. Therefore, to improve diagnostic accuracy, patients with M. tuberculosis who are ANCA positive should be investigated for concurrent diseases, including the effects of drugs. Therefore, even in tuberculosis epidemic area, ANCA seropositivity, detected by ELISA, is still more suggestive of ANCA-associated vasculitides.

ABSTRACT In order to establish an optimal soybean embryonic tip regeneration system that can serve as soybean genetic transformation receptor, and be used for the study of genetic function verification, the influences of single factor on the adventitious bud of embryonic tip induction, elongation and rooting stage, are researched and compared.The single factors includes seeds soaking time, different kinds of hormones, different concentration of hormone and different concentration of sucrose. By one-way ANOVA and LSD ad hoc test , the results show that, for the embryonic tip adventitious bud induction stage, 12h is the optimal seeds soaking time, 2.0mg·L-1 is the optimal concentration of 6-Benzyl Aminopurine(6-BA), for the embryonic tip adventitious bud elongation stage, 0.2mg·L-1 indole-3-butyric acid (IBA) is optimal and 2.0mg·L-1Gibberellic acid (GA3) is optimal, and for the adventitious bud of embryonic tip rooting stage, 2.0mg·L-1 IBA is optimal,the average rooting rate is 93.34%. An Optimal embryonic tip regeneration system is established, and optimum mediums in different stages are found.

抽象是在全文可

абстрактный доступен в Полный текст

Résumé Objectif Étudier le rapport coût-efficacité d'un programme global de lutte contre la tuberculose pharmacorésistante lancé en 2011 dans quatre régions chinoises. Méthodes En 2011-2012, nous avons analysé les dossiers de 172 patients atteints de tuberculose pharmacorésistante qui s'étaient inscrits à ce programme global et nous avons collecté des données administratives pertinentes auprès de différents hôpitaux et de l'agence de santé publique chinoise. À titre de comparaison, nous avons examiné une cohorte de 81 patients soignés pour une tuberculose pharmacorésistante entre 2006 et 2009. Nous avons réalisé une analyse coût-efficacité, sur le plan sociétal, qui incluait une incertitude probabiliste. Nous avons mesuré les résultats du traitement précoce en fonction de résultats de culture sur trois mois et modélisé les résultats à long terme pour faciliter l'estimation du coût du programme global par année de vie corrigée du facteur incapacité (AVCI) évitée. Résultats Le programme global coûte 8837 dollars des États-Unis (US$) par patient soigné. Le faible taux d'inscription signifiait que certains coûts fixes par patient étaient plus importants que prévu. Bien que ce programme global se soit révélé 30 fois plus cher que le précédent, il a débouché sur des avantages accrus en matière de santé. Le programme global, qui coûte 639 US$ (intervalle de crédibilité à 95 %: 112 à 1322) par AVCI évitée, satisfait au critère de l'Organisation mondiale de la Santé définissant une intervention très rentable. Conclusion Le programme global, qui incluait un dépistage rapide, des soins standardisés et une protection financière, a amélioré les résultats des patients atteints de tuberculose multirésistante en limitant les dépenses. Afin de soutenir les objectifs mondiaux pour l'après-2015 en matière de santé, le programme global devrait être élargi aux non-résidents et à d'autres régions de Chine.

Abstract Objective To investigate the cost-effectiveness of a comprehensive programme for drug-resistant tuberculosis launched in four sites in China in 2011. Methods In 2011-2012, we reviewed the records of 172 patients with drug-resistant tuberculosis who enrolled in the comprehensive programme and we collected relevant administrative data from hospitals and China's public health agency. For comparison, we examined a cohort of 81 patients who were treated for drug-resistant tuberculosis in 2006−2009. We performed a cost-effectiveness analysis, from a societal perspective, that included probabilistic uncertainty. We measured early treatment outcomes based on three-month culture results and modelled longer-term outcomes to facilitate estimation of the comprehensive programme's cost per disability-adjusted life-year (DALY) averted. Findings The comprehensive programme cost 8837 United States dollars (US$) per patient treated. Low enrolment rates meant that some fixed costs were higher, per patient, than expected. Although the comprehensive programme appeared 30 times more costly than the previous one, it resulted in greater health benefits. The comprehensive programme, which cost US$ 639 (95% credible interval: 112 to 1322) per DALY averted, satisfied the World Health Organization's criterion for a very cost-effective intervention. Conclusion The comprehensive programme, which included rapid screening, standardized care and financial protection, improved individual outcomes for MDR tuberculosis in a cost-effective manner. To support post-2015 global heath targets, the comprehensive programme should be expanded to non-residents and other areas of China.

Resumen Objetivo Investigar la costoeficacia de un programa integral para la tuberculosis farmacorresistente lanzado en cuatro localizaciones de China en 2011. Métodos En 2011-2012, se revisaron los informes de 172 pacientes con tuberculosis farmacorresistente que se habían inscrito en el programa integral y se recogieron datos administrativos relevantes de hospitales y la agencia de salud pública de China. Como término de comparación, se examinó un cohorte de 81 pacientes que habían sido tratados para la tuberculosis farmacorresistente en 2006−2009. Se llevó a cabo un análisis de costoeficacia desde una perspectiva societaria que incluía la incertidumbre probabilística. Se midieron los resultados de los tratamientos tempranos basados en los resultados de un cultivo de tres meses y se modelaron resultados a largo plazo para facilitar la estimación del coste del programa integral de años de vida en función de la discapacidad (AVAD) evitada. Resultados El programa integral costó 8.837 dólares estadounidenses (USD) por paciente tratado. Las bajas tasas de inscripción significaban que algunos de los costes fijos eran mayores por paciente que lo esperado. A pesar de que el programa integral parecía 30 veces más costoso que el anterior, tuvo como resultado unos mejores beneficios para la salud. El programa integral, que costó 639 USD (intervalo de credibilidad del 95%: de 112 a 1.322) por AVAD evitado, satisfizo el criterio de la Organización Mundial de la Salud en cuanto a intervenciones muy costoefectivas. Conclusión El programa integral, que incluía un examen rápido, cuidados estándar y protección financiera, mejoró los resultados individuales de la tuberculosis multirresistente (MR) de una manera costoefectiva. Para apoyar los objetivos de salud globales posteriores a 2015, el programa integral debería expandirse a no residentes y otras áreas de China.